RA PHARMACEUTICALS INC's ticker is RARX and the CUSIP is 74933V108. A total of 1 filers reported holding RA PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $19,822,000 | -1.0% | 412,861 | -3.2% | 0.01% | +50.0% |
| Q4 2019 | $20,019,000 | +93.7% | 426,577 | -2.4% | 0.00% | +100.0% |
| Q3 2019 | $10,333,000 | +28.7% | 436,912 | +63.6% | 0.00% | 0.0% |
| Q2 2019 | $8,030,000 | +44.9% | 267,022 | +7.9% | 0.00% | +100.0% |
| Q1 2019 | $5,542,000 | +78.1% | 247,375 | +44.7% | 0.00% | 0.0% |
| Q4 2018 | $3,112,000 | +3.0% | 171,013 | +2.4% | 0.00% | 0.0% |
| Q3 2018 | $3,021,000 | +100.1% | 166,965 | +10.0% | 0.00% | – |
| Q2 2018 | $1,510,000 | +59.3% | 151,820 | -15.0% | 0.00% | – |
| Q1 2018 | $948,000 | -19.0% | 178,529 | +29.6% | 0.00% | – |
| Q4 2017 | $1,170,000 | -41.3% | 137,715 | +0.9% | 0.00% | -100.0% |
| Q3 2017 | $1,993,000 | -18.3% | 136,508 | +4.9% | 0.00% | 0.0% |
| Q2 2017 | $2,439,000 | +50.0% | 130,126 | +70.3% | 0.00% | – |
| Q1 2017 | $1,626,000 | +44.3% | 76,396 | +3.0% | 0.00% | – |
| Q4 2016 | $1,127,000 | – | 74,188 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 6,138,797 | $294,724,000 | 15.40% |
| RA Capital Management | 4,858,260 | $233,245,000 | 7.37% |
| HAVENS ADVISORS LLC | 143,266 | $6,878,000 | 6.70% |
| BARDIN HILL MANAGEMENT PARTNERS LP | 609,614 | $29,267,000 | 6.40% |
| OMNI PARTNERS LLP | 1,052,744 | $50,542,000 | 4.45% |
| HBK INVESTMENTS L P | 2,004,042 | $96,214,000 | 4.03% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,005,600 | $96,289,000 | 3.83% |
| Versor Investments LP | 1,108,845 | $53,236,000 | 3.53% |
| OXFORD ASSET MANAGEMENT LLP | 461,016 | $22,133,000 | 3.12% |
| HighVista Strategies LLC | 63,222 | $3,035,000 | 2.81% |